phase readout
saveNCT06436742: A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
ACTIVE_NOT_RECRUITINGupdated 10m ago
community read0 votes
Sponsor: argenx. Phase: PHASE1. Conditions: Congenital Myasthenic Syndrome, CMS
view source ↗
comments(0)
5-min edit window · permanent after that